Inmed Pharma Profile
_______ OUR NEW PROFILE IS: (NASDAQ: INM) ______ INM HAS A FLOAT OF 3.3 MILLION WITH $9.6MILL IN CASH (MARCH, 21 2023) AND $2.3MILL IN Q4 REVENUES!! (UNAUDITED) LAST 2 PERIODS SHOW A MASSIVE 123%(UNAUDITED) AND 120% QUARTER OVER QUARTER GROWTH TOTAL REVENUES OF $4.1M (UNAUDITED) IN FISCAL YEAR 2023, REPRESENTING A 276% INCREASE OVER […]
LYT Profile
OUR NEW PROFILE IS: (NASDAQ: LYT) THE FLOAT ON LYT IS A MERE 8.67 MILL SHARES.……. IT IS SITTING UNDER .35 RIGHT NOW!! LYTUS TECHNOLOGIES ENTERS FINTECH SPACE WITH THE LAUNCH OF A NEW PAYMENT GATEWAY IN INDIA LYTUS HAS OVER 4 MILLION ACTIVE USERS, EXCLUSIVE ACCESS TO OVER 5000 KILOMETERS (3106 MILES), AND REPORTED $19 MILLION […]
(Nasdaq: HRYU) Profile
OUR NEW PROFILE IS: (NASDAQ: HRYU) HRYU HAS CLOSED GREEN FOR 7 CONSECUTIVE SESSIONS NOW ALL-IN-ONE SOCIAL EXPERIENCE PLATFORM CONNECTING K-CULTURE FANS AROUND THE WORLD FANTOO SURPASSED 26.6 MILLION REGISTERED USERS GLOBALLY AND ~1.5 MILLION ACTIVE MONTHLY USERS AS OF MARCH 2023 USER ACQUISITION COST OF $0.038 VIEW THE INVESTOR PRESENTATION HERE _______________________________ Hello Everyone, […]
CTXR PROFILE
OUR NEW PROFILE IS: NASDAQ: CTXR “MINO-WRAP” COULD REVOLUTIONIZE $400 MILLION POST-MASTECTOMY INFECTION PREVENTION MARKET $CASH AND CASH EQUIVALENTS OF $33.3 MILLION AS OF JUNE 30, 2023 CTXR) COMPLETED PIVOTAL PHASE 3 TRIAL OF I/ONTAK (E7777) AND SUBMITTED BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) CITIUS PHARMACEUTICALS TO BE […]
(Nasdaq: SKYX) Profile
OUR NEW PROFILE IS: (NASDAQ: SKYX) SKYX HAS OVER 60 U.S. AND GLOBAL PATENTS AND PATENTS PENDING APPLICATIONS WITH 15 ISSUED PATENTS IN THE U.S. AND GLOBALLY SKYX ALREADY HAS A GLOBAL LICENSING AGREEMENT WITH GENERAL ELECTRIC SKYX GENERATED $15 MILLION IN REVENUE IN THE SECOND QUARTER OF 2023 CEILING SMART AND STANDARD PLUG AND PLAY […]
(Nasdaq: IVP) Profile
OUR NEW PROFILE IS: (NASDAQ: IVP) ____________________ REVENUE RUN RATE ~$19M, 13LOCATIONS ACROSS 9 STATES, ~$3.5M IN REI 3 NEW LOCATIONS UNDER LOI WHICH WILL BRING AN ADDITION $6M OF ANNUAL REVENUE AND $2M IN REI THIS ONE JUST IPO’D ON WEDNESDAY AFTER PRICING AT $4.00 A SHARE READ THE INVESTOR PRESENTATION HERE __________________________________________ Hello […]
(Nasdaq: NLSP) Profile
OUR NEW PROFILE IS: (NASDAQ: NLSP) NLSP HAS OVER 100 PATENTS IN 140 DIFFERENT COUNTRIES JASON MCCARTHY FROM MAXIM GROUP INITIATED A “BUY RATING” ON NLSP WITH A $4.00 PRICE TARGET BACK IN JAN NLSP HAS A LOW FLOAT WITH 14.8 MILLION SHARES COUPLED WITH A WELL FUNDED CASH POSITION OF $8.9MILLION (AS OF DEC. […]
(Nasdaq: BNOX) Profile
OUR NEW PROFILE IS: (NASDAQ: BNOX) BNOX HAS CLOSED GREEN THE LAST 4 SESSIONS AND HAS MADE A STRONG MOVE UP THE COMPANY’S CASH BALANCE ON 30 JUNE 2023 WAS $18.25 MILLION READ THE INVESTOR PRESENTATION HERE __________________________________________ Hello Everyone, We have another brand new profile that we have never featured on this newsletter before. […]
ALBT PROFILE
OUR NEW PROFILE IS: (NASDAQ: ALBT) ________________________________________________________________ ALBT HAS FEWER THAN 8.1 MILLION SHARES AVAILABLE IN ITS PUBLIC FLOAT ACCORDING TO MARKETWATCH GLOBOCARE REPORTS LABORATORY SERVICES MSO REVENUE OF $14.7 MILLION AND NET INCOME OF $6.3 MILLION IN 2022 ……………40% PROFIT SHARING ARRANGEMENT WITH LABORATORY SERVICES MSO IS EXPECTED TO RESULT IN SIGNIFICANT FUTURE CASH […]
(Nasdaq: DATS) Profile
OUR NEW PROFILE IS: (NASDAQ: DATS) DATS SEES 1,200 TO 2,500 NEW MEMBERS JOINING HABYTAT DAILY THE COMPANY REPORTED THAT IT HAS PURCHASED 667,691 SHARES OF COMMON STOCK AT AN AVERAGE PRICE OF $0.5949 PER SHARE AS OF 5/31/2023 FROM IT’S $2 MILLION REPURCHASE PROGRAM AUTHORIZED IN JANUARY CHECK OUT THE INVESTOR PRESENTATION HERE ____ Hello Everyone, We […]